2(1H)-Quinolinone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl- (BioDeep_00000842161)
代谢物信息卡片
2(1H)-Quinolinone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-
化学式: C27H22Cl2N4O (488.1171)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
InChI: InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3
描述信息
D000970 - Antineoplastic Agents
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Paula Martinez de la Cruz, Amir Shabaka, Xabier Mielgo-Rubio, Carmen Guerrero-Marquez, Sara Gimenez-Moyano, Gema Fernandez-Juarez. Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patient with Squamous Cell Carcinoma of the Lung.
The American journal of the medical sciences.
2021 07; 362(1):99-102. doi:
10.1016/j.amjms.2021.04.003. [PMID: 33872582] - Xue-Tao Xu, Jie Chen, Xiang Ren, Yu-Ran Ma, Xiao Wang, Yan-Yan Ma, Den-Gao Zhao, Ren-Ping Zhou, Kun Zhang, Susan Goodin, Dong-Li Li, Xi Zheng. Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
European journal of pharmacology.
2021 Feb; 893(?):173840. doi:
10.1016/j.ejphar.2020.173840. [PMID: 33359649] - Jie Guo, Kazuhiro Shirozu, Tomohiko Akahoshi, Yukie Mizuta, Masaharu Murata, Ken Yamaura. The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A.
International immunopharmacology.
2020 Jun; 83(?):106462. doi:
10.1016/j.intimp.2020.106462. [PMID: 32251961] - Ahmed Aboelfotoh Hendy, Junjie Xing, Xiaoyang Chen, Xiao-Lin Chen. The farnesyltransferase β-subunit RAM1 regulates localization of RAS proteins and appressorium-mediated infection in Magnaporthe oryzae.
Molecular plant pathology.
2019 09; 20(9):1264-1278. doi:
10.1111/mpp.12838. [PMID: 31250536] - Kazuhiro Shirozu, Shuichi Hirai, Tomokazu Tanaka, Shinsuke Hisaka, Masao Kaneki, Fumito Ichinose. Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.
Shock (Augusta, Ga.).
2014 Dec; 42(6):570-577. doi:
10.1097/shk.0000000000000239. [PMID: 25046541] - Igor G Nikolov, Nobuhiko Joki, Antoine Galmiche, Thao Nguyen-Khoa, Ida Chiara Guerrera, François Guillonneau, Ognen Ivanovski, Olivier Phan, Julien Maizel, Frédéric Marçon, Joyce Benchitrit, Anthony Lucas, Aleksander Edelman, Bernard Lacour, Tilman B Drüeke, Ziad A Massy. Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.
Atherosclerosis.
2013 Jul; 229(1):42-51. doi:
10.1016/j.atherosclerosis.2013.02.041. [PMID: 23672878] - Frederick S Buckner, Maria Terezinha Bahia, Praveen Kumar Suryadevara, Karen L White, David M Shackleford, Naveen Kumar Chennamaneni, Matthew A Hulverson, Joy U Laydbak, Eric Chatelain, Ivan Scandale, Christophe L M J Verlinde, Susan A Charman, Galina I Lepesheva, Michael H Gelb. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Antimicrobial agents and chemotherapy.
2012 Sep; 56(9):4914-21. doi:
10.1128/aac.06244-11. [PMID: 22777048] - Niranjan Yanamandra, Robert W Buzzeo, Mark Gabriel, Lori A Hazlehurst, Yelenis Mari, Darrin M Beaupre, Javier Cuevas. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
The Journal of pharmacology and experimental therapeutics.
2011 Jun; 337(3):636-43. doi:
10.1124/jpet.110.172809. [PMID: 21378206] - Brigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, Elizabeth Fox, Peter Zannikos, Wendy Goodspeed, Anne Goodwin, John J Wright, Susan M Blaney, Peter C Adamson, Frank M Balis. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Pediatric blood & cancer.
2011 Feb; 56(2):226-33. doi:
10.1002/pbc.22775. [PMID: 20860038] - Mandy Geryk-Hall, Yanwen Yang, Dennis P M Hughes. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
Molecular cancer therapeutics.
2010 May; 9(5):1111-9. doi:
10.1158/1535-7163.mct-09-0833. [PMID: 20406948] - Brian C Capell, Michelle Olive, Michael R Erdos, Kan Cao, Dina A Faddah, Urraca L Tavarez, Karen N Conneely, Xuan Qu, Hong San, Santhi K Ganesh, Xiaoyan Chen, Hedwig Avallone, Frank D Kolodgie, Renu Virmani, Elizabeth G Nabel, Francis S Collins. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Proceedings of the National Academy of Sciences of the United States of America.
2008 Oct; 105(41):15902-7. doi:
10.1073/pnas.0807840105. [PMID: 18838683] - David S Hong, Srini B Reddy, Victor G Prieto, John J Wright, Nizar M Tannir, Philip R Cohen, A Hafeez Diwan, Harry L Evans, Razelle Kurzrock. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Archives of dermatology.
2008 Jun; 144(6):779-82. doi:
10.1001/archderm.144.6.779. [PMID: 18559769] - Juan Jose Perez-Ruixo, Wei Chen, Steven Zhang, Siobhan Hayes, Andrew Chow. Exposure-toxicity relationships for tipifarnib in cancer patients.
British journal of clinical pharmacology.
2007 Aug; 64(2):219-32. doi:
10.1111/j.1365-2125.2007.02883.x. [PMID: 17378913] - Ahmad Awada, Steven Zhang, Thierry Gil, Dominique de Valeriola, Yassine Lalami, Peter De Porre, Martine J Piccart-Gebhart. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Current medical research and opinion.
2007 May; 23(5):991-1003. doi:
10.1185/030079907x178810. [PMID: 17519066] - L Gore, S N Holden, R B Cohen, M Morrow, A S Pierson, C L O'Bryant, M Persky, D Gustafson, C Mikule, S Zhang, P A Palmer, S G Eckhardt. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2006 Nov; 17(11):1709-17. doi:
10.1093/annonc/mdl282. [PMID: 16980604] - Wandena S Siegel-Lakhai, Mirjam Crul, Peter De Porre, Steven Zhang, Ilsung Chang, Henk Boot, Jos H Beijnen, Jan H M Schellens. Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Oct; 24(28):4558-64. doi:
10.1200/jco.2006.05.8123. [PMID: 17008695] - Steven Zhang, Peter Zannikos, Ahmad Awada, Martine Piccart-Gebhart, Luc Y Dirix, Pierre Fumoleau, Tom Verhaeghe, Marc Francois, Peter De Porre. Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
Journal of clinical pharmacology.
2006 Oct; 46(10):1116-27. doi:
10.1177/0091270006291034. [PMID: 16988200] - Brigitte C Widemann, Wanda L Salzer, Robert J Arceci, Susan M Blaney, Elizabeth Fox, David End, Andrea Gillespie, Patricia Whitcomb, Joseph S Palumbo, Aaron Pitney, Nalini Jayaprakash, Peter Zannikos, Frank M Balis. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006 Jan; 24(3):507-16. doi:
10.1200/jco.2005.03.8638. [PMID: 16421428] - W S Siegel-Lakhai, M Crul, S Zhang, R W Sparidans, D Pluim, A Howes, B Solanki, J H Beijnen, J H M Schellens. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer.
2005 Nov; 93(11):1222-9. doi:
10.1038/sj.bjc.6602850. [PMID: 16251868] - Timothy F Cloughesy, John Kuhn, H Ian Robins, Lauren Abrey, Patrick Wen, Karen Fink, Frank S Lieberman, Minesh Mehta, Susan Chang, Alfred Yung, Lisa DeAngelis, David Schiff, Larry Junck, Morris Groves, Steve Paquette, John Wright, Kathleen Lamborn, Said M Sebti, Michael Prados. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2005 Sep; 23(27):6647-56. doi:
10.1200/jco.2005.10.068. [PMID: 16170172] - Jonathan E Rosenberg, Hans von der Maase, John D Seigne, Jozef Mardiak, David J Vaughn, Malcolm Moore, Deepak Sahasrabudhe, Peter A Palmer, Juan Jose Perez-Ruixo, Eric J Small. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Cancer.
2005 May; 103(10):2035-41. doi:
10.1002/cncr.21023. [PMID: 15812833] - M Caraglia, A Budillon, P Tagliaferri, M Marra, A Abbruzzese, F Caponigro. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Current drug targets.
2005 May; 6(3):301-23. doi:
10.2174/1389450053765833. [PMID: 15857290] - Sarah J O'Meara, B Therese Kinsella. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.
British journal of pharmacology.
2004 Sep; 143(2):318-30. doi:
10.1038/sj.bjp.0705956. [PMID: 15339863] - J V Heymach, D H Johnson, F R Khuri, H Safran, L L Schlabach, F Yunus, R F DeVore, P M De Porre, H M Richards, X Jia, S Zhang, B E Johnson. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2004 Aug; 15(8):1187-93. doi:
10.1093/annonc/mdh315. [PMID: 15277257] - Steven J Cohen, James Gallo, Nancy L Lewis, R Katherine Alpaugh, Louis Gentner, André Rogatko, Gwen Yeslow, Jessie Schol, Tom Verhaeghe, Peter Zannikos, Peter A Palmer, Louis M Weiner, Neal J Meropol. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cancer chemotherapy and pharmacology.
2004 Jun; 53(6):513-8. doi:
10.1007/s00280-004-0764-7. [PMID: 14760509] - Razelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, Neil Singhania, Deborah A Thomas, Edward F Wilson, John J Wright, Emil J Freireich, Moshe Talpaz, Saïd M Sebti. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Blood.
2003 Dec; 102(13):4527-34. doi:
10.1182/blood-2002-11-3359. [PMID: 12947010] - Amita Patnaik, S Gail Eckhardt, Elzbieta Izbicka, Anthony A Tolcher, Lisa A Hammond, Chris H Takimoto, Garry Schwartz, Heather McCreery, Andrew Goetz, Masataka Mori, Kazutoyo Terada, Lou Gentner, Mary-Ellen Rybak, Henry Richards, Steven Zhang, Eric K Rowinsky. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Oct; 9(13):4761-71. doi:
NULL. [PMID: 14581347] - Johann S de Bono, Anthony W Tolcher, Eric K Rowinsky. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Seminars in oncology.
2003 Oct; 30(5 Suppl 16):79-92. doi:
10.1053/j.seminoncol.2003.08.010. [PMID: 14613029] - J L Liesveld, J E Lancet, K E Rosell, A Menon, C Lu, C McNair, C N Abboud, J D Rosenblatt. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
Leukemia.
2003 Sep; 17(9):1806-12. doi:
10.1038/sj.leu.2403063. [PMID: 12970780] - Wolfram C Dempke. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Anticancer research.
2003 Mar; 23(2A):813-8. doi:
. [PMID: 12820305] - Jorge Cortes, Maher Albitar, Deborah Thomas, Francis Giles, Razelle Kurzrock, Alain Thibault, Wayne Rackoff, Charles Koller, Susan O'Brien, Guillermo Garcia-Manero, Moshe Talpaz, Hagop Kantarjian. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood.
2003 Mar; 101(5):1692-7. doi:
10.1182/blood-2002-07-1973. [PMID: 12411300] - S Le Gouill, C Pellat-Deceunynck, J-L Harousseau, M-J Rapp, N Robillard, R Bataille, M Amiot. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Leukemia.
2002 Sep; 16(9):1664-7. doi:
10.1038/sj.leu.2402629. [PMID: 12200678] - Francesco Caponigro. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Anti-cancer drugs.
2002 Sep; 13(8):891-7. doi:
10.1097/00001813-200209000-00016. [PMID: 12394276] - R C Garner, I Goris, A A E Laenen, E Vanhoutte, W Meuldermans, S Gregory, J V Garner, D Leong, M Whattam, A Calam, C A W Snel. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor.
Drug metabolism and disposition: the biological fate of chemicals.
2002 Jul; 30(7):823-30. doi:
10.1124/dmd.30.7.823. [PMID: 12065441] - M Crul, G J de Klerk, M Swart, L Weiner, P A Palmer, C J Bol, J H Beijnen, J H M Schellens. Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics.
2002 Jan; 27(1):61-5. doi:
10.1007/bf03190407. [PMID: 11996329] - J E Karp, J E Lancet, S H Kaufmann, D W End, J J Wright, K Bol, I Horak, M L Tidwell, J Liesveld, T J Kottke, D Ange, L Buddharaju, I Gojo, W E Highsmith, R T Belly, R J Hohl, M E Rybak, A Thibault, J Rosenblatt. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Blood.
2001 Jun; 97(11):3361-9. doi:
10.1182/blood.v97.11.3361. [PMID: 11369625] - C J Punt, L van Maanen, C J Bol, W F Seifert, D J Wagener. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Anti-cancer drugs.
2001 Mar; 12(3):193-7. doi:
10.1097/00001813-200103000-00003. [PMID: 11290865] - J Zujewski, I D Horak, C J Bol, R Woestenborghs, C Bowden, D W End, V K Piotrovsky, J Chiao, R T Belly, A Todd, W C Kopp, D R Kohler, C Chow, M Noone, F T Hakim, G Larkin, R E Gress, R B Nussenblatt, A B Kremer, K H Cowan. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2000 Feb; 18(4):927-41. doi:
10.1200/jco.2000.18.4.927. [PMID: 10673536]
